RAUltragenyx Pharmaceutical RARE · NASDAQ
$16.02 +6.30% (+$0.95)
- Market cap
- $1.58B
- Enterprise value
- $2.66B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 2.2x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -53.8%
- Gross margin
- 83.1%
- Net margin
- -81.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.32
- Free float
- 96.1%
About the company
Ultragenyx Pharmaceutical is a biotechnology company focused on developing innovative therapeutic options for rare genetic diseases. The company specializes in developing drugs that target specific genetic mutations or metabolic pathways that cause various rare diseases, including genetic disorders that affect metabolism, growth, and development. Ultragenyx focuses on conditions for which there are limited available treatment options and strives to improve the lives of patients with these diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Emil D. Kakkis
Employees
1,371
Headquarters
Novato
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number